Combination HIV Prevention Interventions: The Potential of Integrated Behavioral and Biomedical Approaches

Current HIV/AIDS Reports

Volumn 11, Issue 4, 2014, Pages 363-375

  Brown, Jennifer L ^a   Sales, Jessica M ^b,c   DiClemente, Ralph J ^b,c  

^a TEXAS TECH UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY CENTER FOR AIDS RESEARCH   (United States)

Author keywords

Behavioral HIV prevention; Biomedical HIV prevention; Combination HIV prevention; HIV vaccine; Microbicide; PrEP

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROBICIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

DRUG EFFICACY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PROPHYLAXIS; PROSTITUTION; REVIEW; VACCINATION; ATTITUDE TO HEALTH; FEMALE; HIV INFECTIONS; MALE; PRE-EXPOSURE PROPHYLAXIS; PROCEDURES;

AIDS VACCINES; ANTI-HIV AGENTS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; MALE; PRE-EXPOSURE PROPHYLAXIS;

EID: 84919415847     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-014-0228-6     Document Type: Review

References (86)

1. CDC. Estimated HIV incidence among adults and adolescents in the United States, 2007–2010. HIV Surveillance Supplemental Report 2012, 17.
2. WHO. Core epidemiological slides: HIV/AIDS estimates. 2013.
3. Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep. 2011;8:62–72. This article overviews potential strategies to develop, evaluate, and implement combination HIV prevention approaches and notes currently funded combination HIV prevention trials.
4. Alsallaq RA, Baeten JM, Celum CL, Hughes JP, Abu-Raddad LJ, Barnabas RV, et al. Understanding the potential impact of a combination HIV prevention intervention in a hyper-endemic community. PLoS ONE. 2013;8:1–13.
5. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376:285–301.
6. Hankins CA, de Zalduondo BO. Combination prevention: a deeper understanding of effective HIV prevention. AIDS. 2010;24:S70–80. This paper describes strategies for implementation of combination HIV prevention approaches at different system levels which are tailored to a particular culture.
7. CDC. Effective interventions: HIV prevention that works. Atlanta: CDC; 2014.
8. Galbraith JS, Herbst JH, Whittier DK, Jones PL, Smith BD, Uhl G, et al. Taxonomy for strengthening the identification of core elements for evidence-based behavioral interventions for HIV/AIDS prevention. Health Educ Res. 2011;26:872–85.
9. Bentley ME, Fullem AM, Tolley EE, Kelly CW, Jogelkar N, Srirak N, et al. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am J Public Health. 2004;94:1159–64.
10. Cutler B, Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis. 2008;8:685–97.
11. Obiero J, Mwethera PG, Hussey GD, Wiysonge CS. Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infect Dis. 2012;12:289.
12. Mantell JE, Myer L, Carballo-Diéguez A, Stein Z, Ramjee G, Morar NS, et al. Microbicide acceptability research: current approaches and future directions. Soc Sci Med. 2005;60:319–30.
13. Nodin N, Carballo-Dieguez A, Ventuneac AM, Balan IC, Remien R. Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback. AIDS Care. 2008;20:106–15.
14. Weeks MR, Mosack KE, Abbott M, Sylla LN, Valdes B, Prince M. Microbicide acceptability among high-risk urban U.S. women: experiences and perceptions of sexually transmitted HIV prevention. Sex Transm Dis. 2004;31:682–90.
15. Mantell JE, Morar NS, Myer L, Ramjee G. ‘We have our protector’: misperceptions of protection against HIV among participants in a microbicide efficacy trial. Am J Public Health. 2006;96:1073–7.
16. Rustomjee R, Karim QA, Abdool Karim SS, Laga M, Stein Z. Phase 1 trial of nonoxynol-9 film among sex workers in South Africa. AIDS. 1999;13:1511–5.
17. El-Sadr WM, Mayer KH, Maslankowski L, Hoesley C, Justman J, Gai F, et al. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS. 2006;20:1109–16.
18. Woodsong C, Alleman P. Sexual pleasure, gender power and microbicide acceptability in Zimbabwe and Malawi. AIDS Educ Prev. 2008;20:171–87.
19. Tabet SR, Callahan MM, Mauck CK, Gai F, Coletti AS, Profy AT, et al. Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men. J Acquir Immune Defic Syndr. 2000;2003(33):476–83.
20. Morrow K, Rosen R, Richter L, Emans A, Forbes A, Day J, et al. The acceptability of an investigational vaginal microbicide, PRO 2000 gel, among women in a phase I clinical trial. J Women’s Health. 2003;12:655.
21. van der Straten A, Montgomery ET, Cheng H, Wegner L, Masenga G, von Mollendorf C, et al. High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. AIDS Behav. 2012;16:1775–86.
22. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–74.
23. Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006;20:543–51.
24. Rosen RK, Morrow KM, Carballo-Diéguez A, Mantell JE, Hoffman S, Gai F, et al. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. J Women’s Health. 2008;17:383–92.
25. Morrow KM, Ruiz MS. Assessing microbicide acceptability: a comprehensive and integrated approach. AIDS Behav. 2008;12:272–83.
26. Young I, McDaid L. How acceptable are antiretrovirals for the prevention of sexually transmitted HIV?: a review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention. AIDS Behav. 2014;18:195–216.
27. FDA. FDA approves first drug for reducing the risk of sexually acquired HIV infection. Edited by U.S. Department of Health and Human Services. Silver Spring, MD; 2012.
28. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.
29. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–34.
30. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.
31. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411–22.
32. Barash EA, Golden M. Awareness and use of HIV pre-exposure prophylaxis among attendees of a Seattle gay pride event and sexually transmitted disease clinic. AIDS Patient Care STDs. 2010;24:689–91.
33. Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50:77–83.
34. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54:548–55.
35. Underhill K, Morrow KM, Operario D, Mayer KH. Could FDA approval of pre-exposure prophylaxis make a difference? A qualitative study of PrEP acceptability and FDA perceptions among men who have sex with men. AIDS Behav. 2014;18:241–9.
36. Lorente N, Fugon L, Carrieri MP, Andreo C, Le Gall J-M, Cook E, et al. Acceptability of an “on-demand” pre-exposure HIV prophylaxis trial among men who have sex with men living in France. AIDS Care. 2012;24:468–77.
37. Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee S-J, Leibowitz AA. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care. 2011;23:1136–45.
38. Brooks RA, Landovitz RJ, Kaplan RL, Lieber E, Lee S-J, Barkley TW. Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study. AIDS Patient Care STDs. 2012;26:87–94.
39. Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLos ONE. 2012;7:e28238.
40. Galea JT, Kinsler JJ, Salazar X, Lee SJ, Giron M, Sayles JN, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22:256–62.
41. Schneider J, Kumar R, Dandona R, Kumar P, Kumar A, Lakshmi V, et al. Social network and risk-taking behavior most associated with rapid HIV testing, circumcision, and preexposure prophylaxis acceptability among high-risk Indian men. AIDS Patient Care STDs. 2012;26:631–40.
42. Khawcharoenporn T, Kendrick S, Smith K. HIV risk perception and preexposure prophylaxis interest among a heterosexual population visiting a sexually transmitted infection clinic. AIDS Patient Care STDs. 2012;26:222–33.
43. Smith DK, Toledo L, Smith DJ, Adams MA, Rothenberg R. Attitudes and program preferences of African-American urban young adults about pre-exposure prophylaxis (PrEP). AIDS Educ Prev. 2012;24:408–21.
44. Tellalian D, Maznavi K, Bredeek F, Hardy WD. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDs. 2013;27:553–9.
45. Puro V, Palummieri A, De Carli G, Piselli P, Ippolito G. Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists. BMC Infect Dis. 2013;13:217.
46. Guest G, Shattuck D, Johnson L, Akumatey B, Clarke EE, Chen PL, et al. Acceptability of PrEP for HIV prevention among women at high risk for HIV. J Women’s Health. 2010;19:791–8.
47. Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2013;17:2162–72.
48. Mutua G, Sanders E, Mugo P, Anzala O, Haberer JE, Bangsberg D, et al. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLos ONE. 2012;7:e33103.
49. Heffron R, Ngure K, Mugo N, Celum C, Kurth A, Curran K, et al. Willingness of Kenyan HIV-1 serodiscordant couples to use antiretroviral-based HIV-1 prevention strategies. J Acquir Immune Defic Syndr. 2012;61:116–9.
50. Ware NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, Psaros C, et al. What’s love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr. 2012;59:463–8.
51. Kibengo FM, Ruzagira E, Katende D, Bwanika AN, Bahemuka U, Haberer JE, et al. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLos ONE. 2013;8:e74314.
52. Minnis AM, Gandham S, Richardson BA, Guddera V, Chen BA, Salata R, et al. Adherence and acceptability in MTN001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav. 2013;17:737–47.
53. Dolin R. HIV vaccine trial results—an opening for further research. N Engl J Med. 2009;361:2279–80.
54. Dhalla S, Poole G. Motivators of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies. AIDS Care. 2011;23:1430–47.
55. Mills E, Cooper C, Guyatt G, Gilchrist A, Rachlis B, Sulway C, et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS. 2004;18:2235–42.
56. Newman PA, Logie C. HIV vaccine acceptability: a systematic review and meta-analysis. AIDS. 2010;24:1749–56.
57. Jaspan HB, Berwick JR, Myer L, Mathews C, Flisher AJ, Wood R, et al. Adolescent HIV prevalence, sexual risk, and willingness to participate in HIV vaccine trials. J Adolesc Health. 2006;39:642–8.
58. Sayles JN, Macphail CL, Newman PA, Cunningham WE. Future HIV vaccine acceptability among young adults in South Africa. Health Educ Behav. 2010;37:193–210.
59. Webb PM, Zimet GD, Mays R, Fortenberry JD. HIV immunization: acceptability and anticipated effects on sexual behavior among adolescents. J Adolesc Health. 1999;25:320–2.
60. Liau A, Zimet GD. The acceptability of HIV immunization: examining vaccine characteristics as determining factors. AIDS Care. 2001;13:643–50.
61. Liau A, Zimet GD. Undergraduates’ perception of HIV immunization: attitudes and behaviours as determining factors. Int J STD AIDS. 2000;11:445–50.
62. Ravert RD, Zimet GD. College student invulnerability beliefs and HIV vaccine acceptability. Am J Health Behav. 2009;33:391–9.
63. Newman PA, Woodford MR, Logie C. HIV vaccine acceptability and culturally appropriate dissemination among sexually diverse Aboriginal peoples in Canada. Glob Public Health. 2012;7:87–100.
64. Lee S-J, Brooks RA, Newman PA, Seiden D, Sangthong R, Duan N. HIV vaccine acceptability among immigrant Thai residents in Los Angeles: a mixed-method approach. AIDS Care. 2008;20:1161–8.
65. Li Q, Luo F, Zhou Z, Li S, Liu Y, Li D, et al. Willingness to participate in HIV vaccine clinical trials among Chinese men who have sex with men. Vaccine. 2010;28:4638–43.
66. Newman PA, Roungprakhon S, Tepjan S, Yim S. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine. 2010;28:958–64.
67. Kakinami L, Newman PA, Lee S-J, Duan N. Differences in HIV vaccine acceptability between genders. AIDS Care. 2008;20:542–6.
68. Newman PA, Duan N, Lee S-J, Rudy ET, Seiden DS, Kakinami L, et al. HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics. Vaccine. 2006;24:2094–101.
69. Rudy ET, Newman PA, Duan N, Kelly EM, Roberts KJ, Seiden DS. HIV vaccine acceptability among women at risk: perceived barriers and facilitators to future HIV vaccine uptake. AIDS Educ Prev. 2005;17:253–67.
70. Newman PA, Duan N, Kakinami L, Roberts K. What can HIV vaccine trials teach us about future HIV vaccine dissemination? Vaccine. 2008;26:2528–36.
71. Strauss RP, Sengupta S. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. Communities. J Acquir Immune Defic Syndr. 2001;26:63.
72. Newman PA, Duan N, Roberts KJ, Seiden D, Rudy ET, Swendeman D, et al. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J Acquir Immune Defic Syndr. 2006;41:210–7.
73. Buchbinder SP, Metch B, Holte SE, Scheer S, Coletti A, Vittinghoff E. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr. 2004;36:604–12.
74. Colfax G, Buchbinder S, Vamshidar G, Celum C, McKirnan D, Neidig J, et al. Motivations for participating in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2005;39:359–64.
75. Dhawan D, Mayer KH. Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection. J Infect Dis. 2006;193:36–44.
76. Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende N, Mansoor LE, et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials. 2011;12:67.
77. Underhill K, Operario D, Mimiaga MJ, Skeer MR, Mayer KH. Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep. 2010;7:210–9.
78. Curran JW, Crosby RA. Pre-exposure prophylaxis for HIV: who will benefit and what are the challenges? Am J Prev Med. 2013;44:S163–6.
79. Kelesidis T, Landovitz RJ. Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep. 2011;8:94–103.
80. Wilson DP, Coplan PM, Wainberg MA, Blower SM. The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc Natl Acad Sci U S A. 2008;105:9835–40.
81. Cohen MS, Baden LR. Preexposure prophylaxis for HIV—where do we go from here? N Engl J Med. 2012;367:459–61.
82. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26:F13–9.
83. Mills E, Nixon S, Singh S, Dolma S, Nayyar A, Kapoor S. Enrolling women into HIV preventive vaccine trials: an ethical imperative but a logistical challenge. PLos Med. 2006;3:e94.
84. Hosek SG, Siberry G, Bell M, Lally M, Kapogiannis B, Green K, et al. The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men. J Acquir Immune Defic Syndr. 2013;62:447–56.
85. Katz MH. Pre-exposure prophylaxis for HIV: can it be implemented in the real world? Am J Prev Med. 2013;44:S161–2.
86. Warren MJ, Bass ES. From efficacy to impact: an advocate’s agenda for HIV pre-exposure prophylaxis implementation. Am J Prev Med. 2013;44:S167–70.